Liquidia (LQDA) Cash from Investing Activities (2020 - 2026)
Liquidia's (LQDA) quarterly Cash from Investing Activities came in at -$2.8 million in Q1 2026, down 757.58% year-on-year from $430368.7 in Q1 2025, and up 29.92% quarter-over-quarter from -$4.0 million in Q4 2025.
Liquidia (LQDA) Cash from Investing Activities (2020 - 2026) Analysis & Trends
Liquidia's Cash from Investing Activities history runs 7 years deep, the most recent figure standing at -$2.8 million for Q1 2026.
- On a quarterly basis, Cash from Investing Activities fell 757.58% year-over-year to -$2.8 million in Q1 2026; TTM through Mar 2026 was -$8.8 million, a 8.46% decrease from a year earlier, with the FY2025 full-year figure at -$6.3 million, up 24.94% from the prior year.
- Cash from Investing Activities rose to -$2.8 million in Q1 2026 per LQDA's latest filing, from -$4.0 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at -$2000.0 in Q2 2022 and bottomed at -$10.5 million in Q3 2023.
- The 5-year median for Cash from Investing Activities is -$767500.0 (2024), against an average of -$1.8 million.
- Across the five-year window, Cash from Investing Activities surged 94.29% in 2022 and tumbled 12050.0% in 2023, its largest moves.
- Year by year, Cash from Investing Activities stood at -$491000.0 in 2022, then surged by 58.04% to -$206000.0 in 2023, then sank by 2220.39% to -$4.8 million in 2024, then increased by 15.52% to -$4.0 million in 2025, then climbed by 29.92% to -$2.8 million in 2026.
- Per Business Quant, the three latest LQDA Cash from Investing Activities figures stand at -$2.8 million (Q1 2026), -$4.0 million (Q4 2025), and -$911000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 229.00 Mn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | -87.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -369.95 Mn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 743.70 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 277.40 Mn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | -506.20 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | -60.00 Mn |
| 10 | Liquidia | 7.47 Bn | 7.25 Bn | 121.79 Mn | -2.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.83 Mn |
| Mar 31, 2026 | -2.83 Mn |
| Dec 31, 2025 | -4.04 Mn |
| Dec 31, 2025 | -4.04 Mn |
| Sep 30, 2025 | -911,000.00 |
| Sep 30, 2025 | -911,000.00 |
| Jun 30, 2025 | -1.06 Mn |
| Jun 30, 2025 | -1.06 Mn |
| Mar 31, 2025 | -330,000.00 |
| Mar 31, 2025 | -330,000.00 |
| Dec 31, 2024 | -4.78 Mn |
| Dec 31, 2024 | -4.78 Mn |
| Sep 30, 2024 | -1.75 Mn |
| Sep 30, 2024 | -1.75 Mn |
| Jun 30, 2024 | -1.29 Mn |
| Jun 30, 2024 | -1.29 Mn |
| Mar 31, 2024 | -624,000.00 |
| Mar 31, 2024 | -624,000.00 |
| Dec 31, 2023 | -206,000.00 |
| Dec 31, 2023 | -206,000.00 |